How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,010 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia. Full Text available with Trip Pro

The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia. Increasing evidence shows that many metabolic factors are involved in the progression of benign prostatic hyperplasia (BPH). We aimed to assess the relationship between the status of glucose homeostasis and prostate size in aging Chinese males undergoing transurethral resection of the prostate (TURP) for BPH.A total of 1006 medical records of BPH patients undergoing (...) TURP were reviewed. Prostate size was measured by transrectal ultrasound. Annual total prostate (TP) and transitional zone (TZ) growth rates were calculated. According to the American Diabetes Association criteria, the patients were categorized as normoglycemic, prediabetic, or diabetic. Levels of glucose homeostasis and other variables were considered independent variables in an effort to evaluate any potential correlations using non-adjusted and multivariate-adjusted regression models.A total

2020 World journal of urology

42. Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia: outcomes and complications of 10 years of routine clinical practice. (Abstract)

Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia: outcomes and complications of 10 years of routine clinical practice. To assess the perioperative outcomes of holmium laser enucleation of the prostate (HoLEP) in real-life practice and investigate the factors influencing the safety and effectiveness of the technique.Critical analysis of patients with benign prostate hyperplasia (BPH) treated with HoLEP over 10 years (...) of routine practice in three hospitals. Analysed variables included: preoperative characteristics (prostate size, active antiplatelet/anticoagulant therapy, blood parameters. prostate-specific antigen (PSA) level, maximum urinary flow rate [Qmax ], and International Prostate Symptom Score [IPSS]), intraoperative variables (operation time, concomitant removal of bladder calculi, and complications), early postoperative outcomes (change in blood parameters, catheterisation time, and hospital stay), and 12

2020 BJU international

43. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. (Abstract)

The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. To investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and the relationships of MetS and the major pathogenic factors of MetS with the clinical progression of BPH/LUTS in older Chinese men.We analyzed clinical data obtained from 506 ostensibly healthy men who

2020 Prostate

44. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. Full Text available with Trip Pro

Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. Male lower urinary tract symptoms (LUTS) occur in more than half of men above 50 years of age. LUTS were traditionally attributed to benign prostatic hyperplasia (BPH) and therefore the clinical terminology often uses LUTS and BPH interchangeably. More recently, LUTS were also linked to fibrogenic and inflammatory processes. We tested whether osteopontin (OPN), a proinflammatory and profibrotic (...) molecule, is increased in symptomatic BPH. We also tested whether prostate epithelial and stromal cells secrete OPN in response to proinflammatory stimuli and identified downstream targets of OPN in prostate stromal cells.Immunohistochemistry was performed on prostate sections obtained from the transition zone of patients who underwent surgery (Holmium laser enucleation of the prostate) to relieve LUTS (surgical BPH, S-BPH) or patients who underwent radical prostatectomy to remove low-grade prostate

2020 Prostate

45. Efficacy and Safety of 1470-nm Diode Laser Enucleation of the Prostate in Individuals With Benign Prostatic Hyperplasia Continuously Administered Oral Anticoagulants or Antiplatelet Drugs. (Abstract)

Efficacy and Safety of 1470-nm Diode Laser Enucleation of the Prostate in Individuals With Benign Prostatic Hyperplasia Continuously Administered Oral Anticoagulants or Antiplatelet Drugs. To evaluate the efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate (DiLEP) in patients with benign prostatic hyperplasia continuously receiving oral anticoagulants or antiplatelet drugs.From January 2016 to June 2017, 144 patients were submitted to 1470-nm DiLEP, including 49 (34.0 (...) Symptom Score, quality of life score, maximum flow rate, and postvoid residual were markedly improved in both groups at 3-, 6-, and 12-month follow-up postoperatively compared with baseline values. However, no statistically significant differences were observed between the 2 groups in various assessment parameters at follow-up (P > .05).These findings demonstrated that 1470-nm DiLEP is efficient and safe in benign prostatic hyperplasia cases receiving continuous oral anticoagulant or antiplatelet

2020 Urology

46. Efficacy and safety of transurethral split of prostate for benign prostatic hyperplasia: a meta-analysis. Full Text available with Trip Pro

Efficacy and safety of transurethral split of prostate for benign prostatic hyperplasia: a meta-analysis. Transurethral resection of the prostate (TURP) is the first choice for the treatment of benign prostatic hyperplasia. However, Transurethral split of prostate (TUSP) also seems to have clear clinical efficacy and clinical promotion value. To better clarify the potential and limitations of this treatment of prostate hyperplasia. This study objectively evaluated the clinical efficacy (...) to traditional surgical approaches. There were no statistically significant differences in international prostate symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine volume (RUV), or complications between TUSP and traditional approached.TUSP can be an effective alternative for clinical treatment of benign prostatic hyperplasia. Given the limitations of the included studies, more high-quality randomized controlled trials are needed in the future to validate or update the results

2020 BMC Urology

47. Diagnostic performance of transrectal ultrasound for prostate volume estimation in men with benign prostate hyperplasia. (Abstract)

Diagnostic performance of transrectal ultrasound for prostate volume estimation in men with benign prostate hyperplasia. Despite transrectal ultrasound (TRUS) being regarded as gold standard for prostate volume estimation, concerns have been raised in the literature concerning its accuracy especially in men with above-average prostate volumes. We aimed to evaluate the performance of TRUS for prostate volume estimation in a cohort of sub-Saharan African men since they are known to have (...) relatively large mean prostate volumes.This was a prospective study of 77 sub-Saharan African men who had open simple prostatectomy for benign prostate hyperplasia (BPH). Pre-operative TRUS determined total prostate volume (TPV) and transition zone volume (TZV). Following surgical enucleation, the adenoma was weighed (EPW) and its volume (EPV) also determined by fluid displacement. TRUS was repeated six weeks post-operatively to calculate the TRUS-estimated specimen volume (TESV).The mean EPV, EPW, TRUS

2020 International journal of clinical practice

48. Comparison of Hiraoka's Transurethral Detachment Prostatectomy and Transurethral Resection of the Prostate Effects on Postoperative Erectile Function in Patients With Benign Prostatic Hyperplasia: A Prospective Randomized Controlled Study. (Abstract)

Comparison of Hiraoka's Transurethral Detachment Prostatectomy and Transurethral Resection of the Prostate Effects on Postoperative Erectile Function in Patients With Benign Prostatic Hyperplasia: A Prospective Randomized Controlled Study. Currently, no study has focused on the postoperative erectile function in patients with benign prostatic hyperplasia (BPH) by comparing Hiraoka's transurethral detachment of prostate (TUDP) and transurethral resection of prostate (TURP).To compare the effects (...) similar cohorts of patients with BPH who underwent TUDP and TURP, patients who underwent Hiraoka's TUDP experienced greater improvement in postoperative IIEF5 scores than patients who underwent TURP, while improvement in IPSS was similar among both groups. Pan C, Zhan Y, Zhao Y, et al. Comparison of Hiraoka's Transurethral Detachment Prostatectomy and Transurethral Resection of the Prostate Effects on Postoperative Erectile Function in Patients With Benign Prostatic Hyperplasia: A Prospective

2020 Journal Of Sexual Medicine

49. Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia

Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A,Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A,Bardach A, Ciapponi A, López A, Rey-Ares L. Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rápida N° 452. 2016 Authors' conclusions The evidence found

2016 Health Technology Assessment (HTA) Database.

50. Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia. (Abstract)

Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia. 29938670 2018 12 11 2018 12 11 1024-2708 23 Suppl 2 3 2017 06 Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benign prostatic hyperplasia. 35-37 Ng C F CF Division of Urology, Department of Surgery, The Chinese University of Hong Kong. Yee C H CH Division of Urology (...) Urinary Tract Symptoms drug therapy Male Middle Aged Obesity Prospective Studies Prostatic Hyperplasia drug therapy Severity of Illness Index Weight Loss 2018 6 26 6 0 2018 6 26 6 0 2018 12 12 6 0 ppublish 29938670

2018 Hong Kong medical journal = Xianggang yi xue za zhi Controlled trial quality: uncertain

51. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil L Lower urinary tr ower urinary tract symptoms secondary to act symptoms secondary to benign prostatic h benign prostatic hyperplasia: tadalafil yperplasia: tadalafil Evidence summary Published: 23 May 2013 nice.org.uk/guidance/esnm18 pathways Ov Overview erview The content of this evidence summary was up-to-date in May 2013. See summaries of product characteristics (SPCs), British national formulary (BNF (...) ) or the MHRA or NICE websites for up- to-date information. Key points from the evidence T adalafil is a reversible phosphodiesterase type 5 inhibitor available as an oral tablet in various strengths. In October 2012, the 5 mg tadalafil tablet (taken once daily) was granted marketing authorisation to treat signs and symptoms of benign prostatic hyperplasia in adult men. Other strength tablets (2.5 mg, 5 mg, 10 mg and 20 mg) already have marketing authorisation to treat erectile dysfunction in adult men

2013 National Institute for Health and Clinical Excellence - Advice

52. Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer. Full Text available with Trip Pro

Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer. The role of molecular changes in the androgen receptor (AR) as AR variants (AR-Vs) is not clear in the pathophysiology of benign prostatic hyperplasia (BPH) and hormone-naïve PCa. The aim of the current work was to identify the presence of AR isoforms in benign tissue and primary PCa, and to evaluate the possible association with tumor aggressiveness and biochemical recurrence in primary PCa (...) , while AR-CTD and AR-NTD were higher in nuclei of epithelial cells from BPH. These results support the assumption that these constitutively active isoforms of AR are involved in the pathophysiology of primary PCa and BPH. The role of AR-Vs and their possible modulation by steroid tissue levels in distinct types of prostate tumors needs to be elucidated to help guide the best clinical management of these diseases.

2018 PLoS ONE

53. Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria. Full Text available with Trip Pro

Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria. We aimed to determine the usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia. Furthermore, we investigated the clinical characteristics suggesting that patients could benefit from frequency-volume chart assessment in addition to International Prostate (...) Symptom Score assessment.A total of 193 patients with benign prostatic hyperplasia were analyzed. The relationship between the information obtained from the frequency-volume chart and the International Prostate Symptom Score was assessed. Because the urine output per kilogram per hour was not associated with any question in the International Prostate Symptom Score questionnaire, patients were divided into 2 groups according to the presence of global polyuria, defined as urine output >40 mL·kg-1·h-1

2018 PLoS ONE

54. Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia. Full Text available with Trip Pro

Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia. The International Prostate Symptom Score (IPSS) is a useful tool approved by the World Health Organisation and the American Urological Association to measure the severity of lower urinary tract symptoms (LUTS). Although commonly used in urological (...) symptoms in men with Benign prostatic hyperplasia(BPH).The study was designed as a cross-sectional study using researcher-administered IPSS and SQNS questionnaires. The sensitivity, specificity, and correlation coefficient were used to compare the results obtained. Sensitivity was defined as the ability of the SQNS to detect severe-to-moderate symptoms, whereas specificity was defined as the ability of the SQNS to detect mild-to-no symptoms.We recruited 162 patients with an age range between 50 and 88

2018 PLoS ONE

55. Re: Comparison of Prostatic Artery Embolization (PAE) Versus Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia: Randomised, Open Label, Non-inferiority Trial. (Abstract)

Re: Comparison of Prostatic Artery Embolization (PAE) Versus Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia: Randomised, Open Label, Non-inferiority Trial. 30082149 2019 02 07 2019 02 15 1873-7560 74 6 2018 12 European urology Eur. Urol. Re: Comparison of Prostatic Artery Embolization (PAE) Versus Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia: Randomised, Open Label, Non-inferiority Trial. 844 S0302-2838(18)30533-5 10.1016 (...) /j.eururo.2018.07.020 Madersbacher Stephan S Department of Urology, Kaiser Franz Josef Hospital, Sigmund Freud Private University, Vienna, Austria. Electronic address: stephan.madersbacher@wienkav.at. eng Journal Article Comment 2018 08 03 Switzerland Eur Urol 7512719 0302-2838 IM BMJ. 2018 Jun 19;361:k2338 29921613 Arteries Embolization, Therapeutic Humans Male Prostatic Hyperplasia surgery Transurethral Resection of Prostate 2018 07 04 2018 07 11 2018 8 8 6 0 2019 2 8 6 0 2018 8 8 6 0 ppublish

2019 European Urology Controlled trial quality: uncertain

56. Benign prostatic hyperplasia - what do we know? Full Text available with Trip Pro

Benign prostatic hyperplasia - what do we know? To present historical and contemporary hypotheses on the pathogenesis of benign prostatic hyperplasia (BPH), and the potential implications for current medical therapies.The literature on BPH was reviewed. BPH is a prevalent disease with significant health and economic impacts on patients and health organisations across the world, whilst the cause/initiation of the disease process has still not been fully determined.In BPH, pathways involving (...) androgens, oestrogens, insulin, inflammation, proliferative reawakening, stem cells and telomerase have been hypothesised in the pathogenesis of the disease. A number of pathways first described >40 years ago have been first rebuked and then have come back into favour. A system of an inflammatory process within the prostate, which leads to growth factor production, stem cell activation, and cellular proliferation encompassing a number of pathways, is currently in vogue. This review also highlights

2020 BJU international

57. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. (Abstract)

Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. To examine national trends in the medical and surgical treatment of benign prostatic hyperplasia (BPH) using Australian Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) population data from 2000 to 2018.Annual data was extracted from the MBS, PBS and Australian Institute of Health and Welfare databases for the years 2000-2018. Population-adjusted rates (...) monotherapy (149 vs 336 per 100 000 men) since their introduction to the PBS in 2011. Trends in BPH surgery showed an overall progressive increase in rate of total procedures between 2000 and 2018 (92 vs 133 per 100 000 men). Transurethral resection of the prostate (TURP) remained the most commonly performed surgical procedure, despite reduced utilisation since 2009 (118 vs 89 per 100 000 men), offset by a higher uptake of photoselective vaporisation of prostate, holmium:YAG laser enucleation of prostate

2020 BJU international

58. The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. Full Text available with Trip Pro

The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. To evaluate recurrence and progression risk after simultaneous endoscopic surgery of bladder cancer and benign prostatic hyperplasia (BPH), as simultaneous surgery is not an unusual scenario and theoretically simultaneous transurethral resection of bladder tumour (TURBT) and transurethral resection of the prostate (TURP (...) ) can lead to an increased risk of recurrence in the bladder neck and prostatic urethra (BN/PU).We conducted a systematic review and meta-analysis to assess the risk of recurrence (i.e. whole bladder and/or BN/PU) and tumour progression as outcomes after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone. We queried PubMed and Web of Science database on 1 January 2020. We used random- and/or fixed-effects meta-analytic models in the presence or absence

2020 BJU international

59. The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia. Full Text available with Trip Pro

The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia. To provide an update on novel minimally invasive lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) treatments in a non-systematic review. To define potential target populations for the various new minimally invasive treatments.Recent literature, meta-analyses and guideline recommendations for aquablation (AquaBeam® ; PROCEPT (...) BioRobotics, Redwood City, CA, USA), water vapour thermal therapy (Rezūm® ; Boston Scientific, Natick, MA, USA), prostate artery embolisation (PAE), prostatic urethral lift (UroLift® ; NeoTract-Teleflex, Pleasanton, CA, USA) and the temporary implantable nitinol device [i-TIND® (nitinol butterfly-like stent ); Medi-Tate Ltd., Or-Akiva, Israel] were reviewed.Procedures that can be performed on an outpatient basis (Rezūm, PAE, UroLift and i-TIND) are not an alternative for the standard patient requiring BPH

2020 BJU international

60. The effectiveness of electrical stimulation for the management of benign prostatic hyperplasia: A protocol for systematic review and meta analysis. Full Text available with Trip Pro

The effectiveness of electrical stimulation for the management of benign prostatic hyperplasia: A protocol for systematic review and meta analysis. This study will aim to assess the effectiveness and safety of electrical stimulation (ES) for the treatment of patients with benign prostatic hyperplasia (BPH).PubMed, EMBASE, Web of science, Springer, Cochrane Library, PsycINFO, Allied and Complementary Medicine Database, CBM, and China National Knowledge Infrastructure will be retrieved from (...) of ES for the treatment of BPH in several aspects, including changes in urological symptoms, changes in prostate size, urodynamic parameters, quality of life, and number and severity of adverse events.The findings of this study will provide latest evidence to appraise whether ES is an effective and safety intervention for patients with BPH.PROSPERO CRD42019157241.

2020 Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>